$50,000 cost reduction for colon cancer patients?
By jeremy.engdahl-johnson
US Oncology today announced the publication of a study that highlights the savings potential for cancer patients when their treatment is consistent with evidence-based guidelines. Here is an excerpt:
A study conducted by The US Oncology Network and Milliman finds that colon cancer treatment that is consistent with evidence-based guidelines (specifically Level I Pathways) has significantly lower cost while demonstrating outcomes similar to those in published literature. The study shows mean per patient cost differences of more than 30 percent, $53,000 for the treatment of adjuvant colon cancer and $60,000 for the treatment of metastatic colon cancer. The study, which compared patients whose care followed physician-developed Level I Pathways evidence-based guidelines (also known as ‘on pathway’) to other patients (‘off pathway’), was published in a special joint peer-reviewed issue of the Journal of Oncology Practice (JOP) and the American Journal of Managed Care (AJMC).
The full announcement is available here.
Follow us on Twitter
Good for managed care! Less is always more.
Controlled cancer cost may be less, ditto hospice and a funeral, sooner.